Mode
Text Size
Log in / Sign up

Interim Recommendation Issued for Moderna COVID-19 Vaccine in Adults

Interim Recommendation Issued for Moderna COVID-19 Vaccine in Adults
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider this an interim guidance document; await formal trial data for efficacy and safety.

An interim recommendation for the use of the Moderna COVID-19 vaccine has been issued for persons aged 18 years and older in the United States. The source is a recommendation document, not a study report. No study design, phase, sample size, comparator, or follow-up duration is reported.

No specific efficacy or safety data are provided. The main results, primary and secondary outcomes, effect sizes, and absolute numbers are all not reported. Similarly, adverse events, serious adverse events, discontinuations, and tolerability data are not reported.

Key limitations include the absence of underlying study data. The practice relevance is explicitly framed as an interim recommendation. Clinicians should interpret this as a guidance document to be followed while awaiting the publication of formal clinical trial results and safety monitoring data.

Study Details

EvidenceLevel 5
PublishedDec 2020
View Original Abstract ↓
This report describes the interim recommendation made by the Advisory Committee on Immunization Practices on December 19, 2020, for use of the Moderna COVID-19 vaccine in persons aged ≥18 years.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.